NRXP - NRX Pharmaceuticals, Inc.

QQQ $ 621.89 $ 1.27 (0.2 %)

DIA $ 479.13 $ 5.02 (1.06 %)

SPY $ 683.08 $ 3.13 (0.46 %)

TLT $ 89.91 $ -0.03 (-0.03 %)

GLD $ 378.87 $ -1.14 (-0.3 %)

Previous Close

$ 2.54

Open

$ 2.53

Bid

$ 2.50 x 412

Ask

$ 2.55 x 400

Day's Range

$ 2.48 - $ 2.57

52 Week Range

$ 1.12 - $ 6.01

Volume

267,973

Average Volume

Market Cap

50.05M

Beta (5Y Monthly)

$ 1.25

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-18-2025	06-30-2025	10-Q
2	05-15-2025	03-31-2025	10-Q
3	03-14-2025	12-31-2024	10-K
4	11-14-2024	09-30-2024	10-Q
5	08-14-2024	06-30-2024	10-Q
6	05-14-2024	03-31-2024	10-Q
7	03-29-2024	12-31-2023	10-K
8	08-14-2023	06-30-2023	10-Q
9	05-15-2023	03-31-2023	10-Q
10	03-31-2023	12-31-2022	10-K
11	11-14-2022	09-30-2022	10-Q
12	08-15-2022	06-30-2022	10-Q
13	05-16-2022	03-31-2022	10-Q
14	03-31-2022	12-31-2021	10-K
15	11-15-2021	09-30-2021	10-Q
16	08-16-2021	06-30-2021	10-Q
17	05-21-2021	03-31-2021	10-Q
18	04-01-2021	12-31-2020	10-K
19	11-16-2020	09-30-2020	10-Q
20	08-14-2020	06-30-2020	10-Q
21	05-15-2020	03-31-2020	10-Q
22	03-30-2020	12-31-2019	10-K
23	11-14-2019	09-30-2019	10-Q
24	08-14-2019	06-30-2019	10-Q
25	05-15-2019	03-31-2019	10-Q
26	03-15-2019	12-31-2018	10-K
27	11-08-2018	09-30-2018	10-Q
28	08-08-2018	06-30-2018	10-Q
29	05-15-2018	03-31-2018	10-Q
30	03-23-2018	12-31-2017	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

D. Boral Capital Maintains Buy on NRX Phar...
11/10/2025 18:21:26

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $34 price target.

HOPE Therapeutics Launches First-in-Florid...
11/10/2025 13:14:10

ONE-D is the first reported protocol to achieve remission from treatment-resistant depression with a single day of treatment, u...

alphabet-to-rally-around-22-here-are-10-top-analyst-forecasts-for-thursday

Alphabet To Rally Around 22%? Here Are 10 ...
10/30/2025 11:36:08

Ascendiant Capital Maintains Buy on NRX Ph...
10/30/2025 11:16:02

Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target fro...

D. Boral Capital Maintains Buy on NRX Phar...
10/21/2025 11:11:40

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $34 price target.

HC Wainwright & Co. Reiterates Buy on NRX ...
10/16/2025 10:42:03

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $4...

HC Wainwright & Co. Reiterates Buy on NRX ...
10/01/2025 10:51:10

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $4...

D. Boral Capital Maintains Buy on NRX Phar...
09/29/2025 13:50:29

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ: NRXP) with a Buy and maintains $34 price target.

NRx Pharmaceuticals Re-Files Its Abbreviat...
09/29/2025 12:22:41

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced the re-filing of its Abbr...

D. Boral Capital Maintains Buy on NRX Phar...
09/25/2025 11:38:14

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ: NRXP) with a Buy and maintains $34 price target.

NRx Pharmaceuticals Announces FDA Has Gran...
09/24/2025 12:07:49

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, announced that it was notified yesterday b...

D. Boral Capital Maintains Buy on NRX Phar...
09/08/2025 14:09:46

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $34 price target.

HC Wainwright & Co. Assumes NRX Pharmaceut...
09/08/2025 11:49:22

HC Wainwright & Co. analyst Patrick R. Trucchio assumes NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy rating and announce...

FDA Grants Fast Track To NRx's NRX-100 For...
08/27/2025 12:10:19

US Food and Drug Administration (FDA) has granted Fast Track designation for NRX-100 in the treatment of suicidal ideation in p...

12 Health Care Stocks Moving In Friday's A...
08/22/2025 21:07:35

D. Boral Capital Maintains Buy on NRX Phar...
08/22/2025 11:07:54

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target fr...

12 Health Care Stocks Moving In Tuesday's ...
08/19/2025 12:08:33

D. Boral Capital Maintains Buy on NRX Phar...
08/19/2025 11:18:43

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $31 price target.

NRX Pharmaceuticals Q2 EPS $(0.98) Misses ...
08/18/2025 12:13:58

NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of...

NRx Pharmaceuticals To Release Q2 2025 Fin...
08/13/2025 22:20:34

Conference Call 8:00am ET, Wednesday August 20, 2025WILMINGTON, Del., Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (...